Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 8664631.
- Also identified by PMC identifier 2351214.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This is the first of three papers to review international policies to control spending on drugs and improve the efficiency of drug use. Policies can target three main groups: patients, prescribing doctors, and the drugs industry. In this paper we examine policies aimed at patients, particularly restrictions on reimbursement (such as prescription charges). Rigorous experimental and quasi-experimental studies suggest that policies to limit the level of reimbursement of drugs reduce the use of essential as well as non-essential drugs and may do more harm than good.
Medical subject headings
- Drug Costs
- Health Expenditures
- Health Services Needs and Demand